Opexa to Participate at Upcoming Industry Conferences


THE WOODLANDS, TEXAS - (September 10, 2022) - Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing Tcelna™, a novel T-cell therapy for multiple sclerosis (MS), today announced that Neil Warma, President and Chief Executive Officer, will participate in two upcoming industry conferences. Details regarding these events are as follows:

Intellectual Property Owners Association (IPO) Annual Meeting

This conference will take place September 9-11, 2012 at the JW Marriott Hill County in San Antonio, Texas.

  • Keynote Luncheon Address
    Delivered by Mr. Warma
    Tuesday, September 11, 2012, 12:00 - 1:30 p.m. CT

  • Each year, the organizers of the IPO Annual Meeting invite one CEO to deliver a keynote luncheon address. This year, Mr. Warma has been selected to provide insight on the role of intellectual property rights from the perspective of business.

    The 8™ Annual Burrill Personalized Medicine Meeting

    This meeting of researchers, drug developers, analysts, investors and other life science industry representatives will take place September 13-14, 2012 at the Bentley Reserve & Conference Center in San Francisco.

  • "Personalized Medicine From a Drug Developer's Point of View"
    Panel participation by Mr. Warma
    Friday, September 14, 2012, 9:30 - 10:30 a.m. PT

  • Mr. Warma will join several additional panelists as they discuss the implications that advances in personalized medicine are having on the drug development business. Mr. Warma will share Opexa's experiences regarding the clinical development of Tcelna, the first ever personalized T-cell therapy for MS patients.

    About Opexa

    Opexa Therapeutics, Inc. is dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases such as MS. The Company's leading therapy, Tcelna™, a personalized cellular immunotherapy treatment that is in late stage clinical development for MS. Tcelna is derived from T-cells isolated from peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin and, thereby, reduces the risk of relapse over time.

    For more information, visit the Opexa Therapeutics website at www.opexatherapeutics.com.

    Cautionary Statement Relating to Forward - Looking Information for the Purpose of "Safe Harbor" Provisions of the Private Securities Litigation Reform Act of 1995

    This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words "expects," "believes," "hopes," "anticipates," "estimates," "may," "could," "intends," ""exploring," "evaluating," "progressing," and similar expressions are intended to identify forward-looking statements. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding the development of the Company's product candidate, Tcelna, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: our capital position, the rights and preferences provided to the Series A Convertible Preferred Stock and investors in the convertible secured notes (including a secured interest in all of our assets), the ability of the Company to enter into and benefit from a partnering arrangement for the Company's product candidate, Tcelna, on reasonably satisfactory terms (if at all), our dependence (if partnered) on the resources and abilities of any partner for the further development of Tcelna, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of developing a marketable product, our ability to raise additional capital to continue our treatment development programs and to undertake and complete any further clinical studies for Tcelna, the success of our clinical trials, the efficacy of Tcelna for any particular indication, such as for relapsing remitting MS or secondary progressive MS, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights (including for Tcelna), the risk of litigation regarding our intellectual property rights, the success of third party development and commercialization efforts with respect to products covered by intellectual property rights that the Company may license or transfer, our limited manufacturing capabilities, our dependence on third-party manufacturers, our ability to hire and retain skilled personnel, our volatile stock price, and other risks detailed in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date made. We assume no obligation or undertaking to update any forward-looking statements to reflect any changes in expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. You should, however, review additional disclosures we make in our reports filed with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2011.

    Company Contacts:
    Opexa Therapeutics, Inc.
    Neil K. Warma

    Vida Communication
    Tim Brons